

SARC Semiannual Meeting Agenda
Friday, June 3, 2016

8:00	Opening Remarks	
	Denise Reinke	
8:15	Chawla Rosenfeld Developmental Therapeutics Symposium	
	Introduction	Robert Maki/David Kirsch
	Astrocyte-derived Exosomal microRNA Primes Brain Metastasis Outgrowth	Dihua Yu
	Exosomes as markers for Kaposi Sarcoma progression	Dirk Dittmer
	Circulating tumor DNA: Overview and Applications for Sarcoma	Max Diehn
	<i>Discussion/Q&A</i>	Panel
9:45	Career Development Program	
	2016 Awards	Richard Gorlick & Lee Helman
10:00-10:20	Break	
10:20-10:35	SARC Sarcoma SPORE	
	Update	Raphael Pollock
10:35	SARC Clinical Trials	
	Clinical Trials Update	Scott Okuno
	SARC016: Phase 2 trial of bevacizumab & everolimus in unresectable or metastatic MPNST	Brigitte Widemann
	SARC018-SPORE01: Phase 2 trial of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma	Edwin Choy & Shreyaskumar Patel
	SARC021: Phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic STS	William Tap
	SARC023: Phase 1/2 trial of ganetespib & sirolimus in unresectable or metastatic MPNST	AeRang Kim
	SARC024: Phase 2 trial of regorafenib in refractory lipo, osteo and Ewing/Ewing-like sarcomas	Robert Maki, Richard Riedel, Steven Attia & Christopher Ryan/Lara Davis
	SARC025-SPORE03: Phase 1 trial of niraparib and temozolomide or irinotecan in incurable Ewing sarcoma.	Rashmi Chugh & Sandra Straus
	SARC028: Phase 2 trial of the anti-PD1 antibody pembrolizumab (MK-3475) in patients with advanced sarcomas	Melissa Burgess & Hussein Tawbi
11:55	Closing Remarks/Adjourn	